Skip to main content
. 2018 Dec 19;2018(12):CD011689. doi: 10.1002/14651858.CD011689.pub3

Un Nisa 2012.

Methods 2‐arm active‐controlled randomised trial
Participants 100 women were randomised in a hospital setting in India. The population comprised women of parity 2 to 4, a singleton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women with previous PPH, multiple pregnancy, previous caesarean, macrosomia, pre‐eclampsia, diabetes, cardiac/lung/bleeding/clotting disorders or taking anticoagulants.
Interventions 10 IU of oxytocin administered by an IV bolus versus 500 mcg plus 5 IU of ergometrine plus oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500.
Notes Contact with study authors for additional information: yes. Additional data from authors: no
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Study participants (patients) were divided by lottery system in the 2 groups, each group comprising of 50 patients.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel (performance bias) 
 All outcomes High risk Study participants and caregivers were not blinded to treatment allocations.
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss after the delivery of baby quote "by squeezing the soaked pads and quantifying the amount of blood clots in a kidney tray of standard size to be equal to 500 mL".
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk The study authors did not mention any incomplete outcome data.
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all those who were enrolled and randomly allocated to treatment were included in the analysis, in the groups to which they were randomised.
Funding source Unclear risk Source(s) of funding for the study were not reported.